Grifols, S.A.
Every calculator, already run for GRFS
Open the full toolkit →You have the numbers on GRFS. Get the argument.
A written report on which of these readings actually decide the outcome for Grifols, S.A., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering GRFSAnalyst Price Target Disagreement for Grifols, S.A.
Wall Street's bull case implies +58% from the current price; the bear case implies +35%. Analysts are relatively aligned on GRFS's range.
Ownership & short interest
Insider Trading Activity for GRFS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived…
GRFS — frequently asked
Is GRFS a buy right now?
Wall Street's consensus rating on Grifols, S.A. is none across 2 analysts, with a mean price target of $10.87 (+47% vs. the current $7.41). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is GRFS overvalued?
GRFS trades at 9.9x trailing earnings, against a DCF fair value of $82 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Grifols, S.A.?
Analysts covering Grifols, S.A. (GRFS) range from a bear-case target of $10.00 to a bull-case high of $11.73, with a mean consensus target of $10.87 across 2 analysts. The spread of $1.73 (23% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Grifols, S.A. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Grifols, S.A.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GRFS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Grifols, S.A., in minutes. 3 free reports included with every account — no credit card required.